Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Cancer of unknown primary site.

Pavlidis N, Pentheroudakis G.

Lancet. 2012 Apr 14;379(9824):1428-35. doi: 10.1016/S0140-6736(11)61178-1. Epub 2012 Mar 12. Review.

PMID:
22414598
2.

Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models.

Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, Dalerba P, Adorno M, Lobo N, Bueno J, Dirbas FM, Goswami S, Somlo G, Condeelis J, Contag CH, Gambhir SS, Clarke MF.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18115-20. doi: 10.1073/pnas.1006732107. Epub 2010 Oct 4.

3.

A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.

Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC.

Cell Stem Cell. 2010 Jun 4;6(6):603-15. doi: 10.1016/j.stem.2010.04.001.

4.

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS.

Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.

5.

RhoC expression and head and neck cancer metastasis.

Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, Kumar P, Teknos TN.

Mol Cancer Res. 2009 Nov;7(11):1771-80. doi: 10.1158/1541-7786.MCR-08-0512. Epub 2009 Oct 27.

6.

Identification of selective inhibitors of cancer stem cells by high-throughput screening.

Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES.

Cell. 2009 Aug 21;138(4):645-59. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.

7.

Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity.

Dietrich KA, Schwarz R, Liska M, Grass S, Menke A, Meister M, Kierschke G, Längle C, Genze F, Giehl K.

Biol Chem. 2009 Oct;390(10):1063-77. doi: 10.1515/BC.2009.110.

PMID:
19642867
8.

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

Korkaya H, Paulson A, Iovino F, Wicha MS.

Oncogene. 2008 Oct 16;27(47):6120-30. doi: 10.1038/onc.2008.207. Epub 2008 Jun 30.

9.

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ.

Mol Oncol. 2007 Jun;1(1):84-96. doi: 10.1016/j.molonc.2007.02.004.

10.

The epithelial-mesenchymal transition generates cells with properties of stem cells.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.

Cell. 2008 May 16;133(4):704-15. doi: 10.1016/j.cell.2008.03.027.

11.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G.

Cell Stem Cell. 2007 Nov;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.

12.

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C.

Cell Stem Cell. 2007 Sep 13;1(3):313-23. doi: 10.1016/j.stem.2007.06.002.

13.

Three-dimensional culture models of normal and malignant breast epithelial cells.

Lee GY, Kenny PA, Lee EH, Bissell MJ.

Nat Methods. 2007 Apr;4(4):359-65.

14.

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF.

N Engl J Med. 2007 Jan 18;356(3):217-26.

15.

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

McCabe A, Dolled-Filhart M, Camp RL, Rimm DL.

J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15.

16.

Prospective identification of tumorigenic prostate cancer stem cells.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ.

Cancer Res. 2005 Dec 1;65(23):10946-51.

17.

RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.

Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD.

Breast Cancer Res Treat. 2005 Sep;93(2):101-10.

PMID:
16187229
18.

Modelling glandular epithelial cancers in three-dimensional cultures.

Debnath J, Brugge JS.

Nat Rev Cancer. 2005 Sep;5(9):675-88. Review.

PMID:
16148884
19.

RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis.

Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, Mak TW.

Genes Dev. 2005 Sep 1;19(17):1974-9. Epub 2005 Aug 17.

20.

Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility.

Wheeler AP, Ridley AJ.

Exp Cell Res. 2004 Nov 15;301(1):43-9. Review.

PMID:
15501444
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk